Essential Thrombocythemia – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Essential Thrombocythemia – Drugs In Development, 2024 report and make more profitable business decisions.
Essential thrombocythemia is a chronic myeloproliferative neoplasm in which cells in the bone marrow that produce the blood cells develop and function abnormally. In essential thrombocythemia, there is mainly an overproduction of platelet-forming cells (megakaryocytes) in the marrow. Symptoms of essential thrombocythemia include headache, dizziness, weakness or numbness on one side of the body, slurred speech, and transient ischemic attacks.
The Essential Thrombocythemia drugs in development market research report provide comprehensive information on the therapeutics under development for Essential Thrombocythemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Essential Thrombocythemia and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Essential Thrombocythemia | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 19 molecules, with 18 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Essential Thrombocythemia therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Essential Thrombocythemia pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Essential Thrombocythemia treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AbbVie IncChengdu Jinrui Foundation Biotechnology Co Ltd
F. Hoffmann-La Roche Ltd
Imago BioSciences Inc
Incyte Corp
IO Biotech Inc
Italfarmaco SpA
Johnson & Johnson
MEI Pharma Inc
Millennium Pharmaceuticals Inc
MorphoSys AG
Osaka University
PharmaEssentia Corp
Sino Biopharmaceutical Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Essential Thrombocythemia reports